editor
persist
hepat
e
viru
hev
infect
recognis
immunocompromis
patient
particularli
solid
organ
transplant
sot
recipi
major
case
caus
genotyp
hev
ribavirin
monotherapi
consid
firstlin
reduct
immunosuppress
contraind
unsuccess
treatment
failur
relaps
recognis
limit
altern
treatment
option
current
guidelin
suggest
retreat
prolong
cours
ribavirin
case
intoler
nonrespons
pegyl
interferon
pegifn
contraind
sofosbuvir
shown
inhibit
hev
vitro
date
clinic
case
treat
sofosbuvir
led
hev
clearanc
newer
therapi
investig
none
reach
clinic
use
describ
case
persist
hev
infect
demonstr
clinic
phenotyp
resist
convent
treatment
outcom
convalesc
plasma
cp
therapi
patient
male
persist
hev
infect
background
underli
gastric
margin
lymphoma
mucosa
associ
lymphoid
tissu
oment
involv
treat
chemotherapi
includ
rcvp
rituximab
cyclophosphamid
vincristin
prednisolon
rchop
rituximab
cyclophosphamid
hydroxydaunomycin
vincristin
prednisolon
radiotherapi
year
previous
cure
result
treatment
chronic
autoimmun
neutropenia
support
granulocyt
coloni
stimul
factor
diagnos
hev
viraemia
hev
iuml
antihev
igg
world
health
organ
unitsml
march
although
first
note
rais
liver
enzym
novemb
treat
earli
cours
ribavirin
mg
twice
daili
estim
glomerular
filtrat
rate
bodi
weight
kg
hev
rna
detect
blood
week
treatment
stool
end
treatment
relaps
week
complet
treatment
receiv
second
cours
ribavirin
mg
twice
daili
month
hev
rna
level
remain
high
iuml
ribavirin
discontinu
experienc
side
effect
cessat
ribavirin
signific
rise
liver
enzym
level
next
treat
pegifn
ribavirin
pegasi
lg
weekli
ribavirin
mg
twice
daili
month
signific
fall
hev
rna
illumina
whole
genom
sequenc
hev
targetenrich
protocol
supplementari
method
reveal
develop
multipl
mutat
rnadepend
rnapolymeras
region
previous
describ
patient
fail
ribavirin
therapi
previous
undescrib
mutat
also
detect
third
treatment
cours
treatment
result
summaris
fig
absenc
avail
treatment
attempt
treatment
cp
whilst
patient
continu
therapi
pegifn
ribavirin
four
potenti
plasma
donor
identifi
blood
donor
recent
primari
hev
infect
day
develop
high
level
detect
antihev
igg
sampl
cutoff
optic
densiti
valu
least
hev
rna
neg
plasma
sampl
demonstr
viral
clearanc
archiv
sampl
quantifi
antihev
igg
unitsml
test
abil
neutralis
hev
antigen
hevag
fig
antihev
igg
hevag
detect
use
commerci
assay
fortress
diagnost
antrim
northern
ireland
uk
hevag
neutralis
determin
recent
describ
method
hev
rna
detect
use
intern
control
valid
quantit
hev
pcr
limit
detect
iuml
two
donor
select
donor
c
whose
plasma
greater
unitsml
antihev
igg
highest
hevag
neutralis
activ
test
equival
level
antihev
igg
unitsml
donor
previous
infect
viru
technic
limit
prevent
sequenc
viru
previous
infect
donor
c
establish
apheresi
protocol
follow
convalesc
hev
plasma
team
arrang
plasma
collect
select
donor
plasma
collect
donor
c
week
ml
week
initi
viraem
sampl
donor
week
ml
week
initi
viraem
sampl
donat
test
blood
born
virus
line
nation
donor
guidelin
treatment
approv
newcastl
upon
tyne
hospit
nh
foundat
trust
clinic
govern
team
trust
medic
director
patient
provid
written
inform
consent
procedur
subsequ
public
patient
admit
liver
unit
freeman
hospit
newcastl
observ
given
transfus
ml
cp
hour
apart
blood
sampl
taken
accord
protocol
tabl
baselin
total
white
cell
count
l
neutrophil
l
lymphocyt
l
total
serum
igg
gl
iga
gl
igm
gl
igm
paraprotein
patient
report
advers
effect
infus
observ
temperatur
puls
rate
blood
pressur
respiratori
rate
oxygen
satur
level
conscious
normal
infus
hour
post
infus
blood
test
show
chang
liver
enzym
blood
count
renal
function
infus
level
plasma
hev
rna
patient
vari
significantli
infus
followup
period
fig
level
detect
hevag
show
consist
pattern
fall
postinfus
timepoint
sustain
postinfus
nevertheless
baselin
preinfus
sampl
contain
less
detect
hevag
previou
baselin
sampl
fig
hevag
level
return
baselin
day
follow
complet
infus
particular
note
level
detect
antihev
igg
show
similar
pattern
hevag
level
fall
unitsml
compar
preinfus
sampl
infus
respect
fig
rational
cp
therapeut
option
provid
higher
level
neutralis
antibodi
hev
patient
persist
hev
infect
appear
lower
proport
antihev
igg
capabl
neutralis
hevag
convalesc
acut
hev
infect
furthermor
studi
demonstr
protect
effect
cp
cynomolgu
monkey
hev
challeng
possibl
protect
effect
replac
immunoglobulin
persist
hev
infect
amongst
antibodydefici
patient
case
treatment
hev
cp
therapi
effect
lead
sustain
reduct
hev
load
understand
reason
therapeut
failur
crucial
guid
futur
research
cp
demonstr
mix
result
treat
viral
infect
success
outcom
treatment
sever
acut
respiratori
syndrom
coronaviru
influenza
viru
inconclus
result
ebola
viru
diseas
sinc
hev
latent
stage
integr
host
dna
biolog
plausibl
cp
could
effect
treat
hev
infect
howev
knowledg
cp
therapi
use
attempt
clear
persist
hev
infect
mode
action
cp
therapi
well
understood
expect
neutralis
play
signific
role
hev
virion
plasma
appear
circul
quasienvelop
particl
may
protect
neutralis
antibodi
thu
explain
failur
cp
howev
passiv
transfer
antibodi
effect
prevent
liver
diseas
hepat
viru
hav
infect
similar
quasienvelop
virion
access
import
neutralis
epitop
may
still
possibl
endosom
remov
membran
postul
hav
anticip
higher
titr
neutralis
antibodi
greater
therapeut
effect
therefor
identifi
potenti
hightitr
apheresi
donor
amongst
blood
donor
convalesc
hev
infect
comparison
antihev
igg
titr
hevag
neutralis
capabl
despit
patient
sampl
post
infus
consist
lower
detect
antihev
igg
unitsml
intrigu
remain
difficult
explain
believ
adequ
explain
pure
haemodilut
plasma
volum
sinc
preinfus
level
antihev
igg
plasma
patient
unitsml
similar
lower
level
detect
antihev
donor
c
unitsml
unitsml
nevertheless
may
simpli
insuffici
antibodi
plasma
donat
therapeut
effect
especi
given
fact
patient
alreadi
seroposit
detect
antihev
igg
crucial
observ
signific
fluctuat
hev
rna
follow
plasma
infus
howev
observ
fall
hevag
level
follow
infus
recent
studi
identifi
form
antigen
would
inform
understand
whether
form
hevag
fell
postinfus
patient
whether
secret
form
preferenti
fell
anticip
fall
hevag
level
observ
due
bind
neutralis
secret
form
sinc
would
expect
viral
load
fall
virionassoci
hevag
bound
clear
circul
sinc
import
host
immunosuppress
success
cp
therapi
unknown
sure
import
function
immun
system
treatment
efficaci
patient
heavili
immunosuppress
previous
suffer
chronic
neutropenia
immun
dysfunct
may
hinder
efficaci
cp
therapi
rel
import
band
tcell
respons
clear
hev
infect
understood
howev
tcell
respons
known
import
hevspecif
tcell
respons
detect
expos
healthi
control
absent
sot
recipi
persist
hev
infect
reduc
immunosuppress
target
tcell
eg
tacrolimu
lead
hev
clearanc
describ
unsuccess
treatment
attempt
cp
therapi
case
treatmentrefractori
persist
hev
infect
new
treatment
approach
requir
patient
fail
convent
therapi
addit
virolog
includ
hevag
neutralis
work
illumina
whole
genom
sequenc
fund
nh
blood
transplant
